Inhaled fluticasone in bronchiectasis: A 12 month study

Department of Respiratory and Critical Care Medicine, University Department of Medicine, Queen Mary Hospital, Pokfulam Road, Hong Kong.
Thorax (Impact Factor: 8.56). 04/2005; 60(3):239-43. DOI: 10.1136/thx.2002.003236
Source: PubMed

ABSTRACT The clinical efficacy of inhaled corticosteroid (ICS) treatment has not been evaluated in bronchiectasis, despite the presence of chronic airway inflammation.
After three consecutive weekly visits, 86 patients were randomised to receive either fluticasone 500 mug twice daily (n = 43, 23F, mean (SD) age 57.7 (14.4) years) or matched placebo (n = 43, 34F, 59.2 (14.2) years) and reviewed regularly for 52 weeks in a double blind fashion.
35 and 38 patients in the fluticasone and placebo groups completed the study. Significantly more patients on ICS than on placebo showed improvement in 24 hour sputum volume (OR 2.5, 95% CI 1.1 to 6.0, p = 0.03) but not in exacerbation frequency, forced expiratory volume in 1 second, forced vital capacity, or sputum purulence score. Significantly more patients with Pseudomonas aeruginosa infection receiving fluticasone showed improvement in 24 hour sputum volume (OR 13.5, 95% CI 1.8 to 100.2, p = 0.03) and exacerbation frequency (OR 13.3, 95% CI 1.8 to 100.2, p = 0.01) than those given placebo. Logistic regression models revealed a significantly better response in sputum volume with fluticasone treatment than with placebo among subgroups of patients with 24 hour sputum volume <30 ml (p = 0.04), exacerbation frequency </=2/year (p = 0.04), and sputum purulence score >5 (p = 0.03).
ICS treatment is beneficial to patients with bronchiectasis, particularly those with P. aerurginosa infection.

Download full-text


Available from: Gaik Cheng Ooi, Aug 27, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The bronchiectases are not a homogeneous defined entity since they can be the expression of several aetiologies and, very possibly, of several pathogenic mechanisms that are constituted in a vicious circle of alteration of the mucociliary clearance, inflammation and chronic bacterial infection. The different therapeutic options available try to control these aspects and the final objectives are the control of the symptoms, the prevention of progression and the reduction of morbidity. At present the clinical evidence that supports the treatment of this pathology is scarce, but its multidisciplinary evaluation can change its natural history Las bronquiectasias no son una entidad nosológica homogénea ya que pueden ser la expresión de varias etiologías y, muy posiblemente, de varios mecanismos patogénicos que se constituyen en un círculo vicioso de alteración del aclaramiento mucociliar, inflamación e infección bacteriana crónica. Las diferentes opciones terapéuticas disponibles pretenden controlar estos aspectos y los objetivos finales son el control de los síntomas, la reducción de la morbilidad y la prevención de la progresión. En la actualidad la evidencia clínica que soporta el tratamiento de esta patología es escasa pero la valoración multidisciplinar de la misma puede hacer cambiar su historia natural
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Little has been published on the progression of non-cystic fibrosis bronchiectasis (BX), especially in childhood. Data are needed for prognosis and evaluation of the effectiveness of treatments. A study was undertaken to evaluate the change in lung function over time in children with BX, and to consider covariates and compare them with the local cystic fibrosis (CF) population. Children with BX or CF and > or =3 calendar years of lung function data were identified from hospital clinics. Diagnosis was made by high resolution CT scans, sweat tests, and genetic studies. Lung function performed on a single plethysmograph between 6 and 15 years of age and > or =6 weeks after diagnosis was analysed longitudinally (linear mixed model). The impact of reference equation and "best annual" versus "all data" approaches were evaluated. There were 44 children in each of the BX and CF groups with an overall mean 5.7 calendar years follow up data. The estimated forced expiratory volume in 1 second (FEV(1)) in the BX group had an intercept of 68% predicted (Polgar) at 10 years of age which fell at a rate of 1.9% per annum using "best annual" data compared with 63% and 0.9% using "all data". Those with post-infectious BX or chronic Haemophilus influenzae infection had more severe disease. In CF the FEV(1) ("best annual") intercept was 85% predicted with a slope of -2.9% per annum. The choice of reference equation affected the magnitude of the result but not the conclusions. Children with BX have significant airway obstruction which deteriorates over time, regardless of analysis strategy or reference. Effective interventions are needed to prevent significant morbidity and adult mortality.
    Thorax 05/2006; 61(5):414-8. DOI:10.1136/thx.2005.047332 · 8.56 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To investigate whether corticosteroids are effective in the treatment of plastic bronchitis with hemoptysis. A retrospective, clinical study was undertaken. Thirty two patients with only first episodes of plastic bronchitis with hemoptysis were divided into a steroid group (n=18) treated with glucocorticoids, and a non-steroid group (n=14). The supportive therapy was uniformly applied to both groups, except for glucocorticoids. Variables such as temperature and white blood cell counts were determined. Furthermore, the volume of hemoptysis and bronchial casts were evaluated in detail daily. There was no difference in the demographic data and variables at baseline between both groups (all P>0.05). On days 5, 6, 7 and 8, the volume of hemoptysis was significantly decreased in the steroid group compared with the non-steroid group (43+/-15 mL vs 117+/-33 mL on d 5, 29+/-12 mL vs 97+/-23 mL on d 6, 18+/-10 mL vs 80+/-20 mL on d 7, and 13+/-8 mL vs 66+/-14 mL on d 8; all P<0.05), and on d 10 after fibreoptic bronchoscopy, the cases with bronchial casts was reduced evidently in the steroid group in comparison with the non-steroid group (OR=5.69, 95% CI=1.76-43.6; P=0.005). There was no significance in mechanical ventilation and mortality between both groups. Despite some limitations of this study, it has been demonstrated that, on the basis of common supportive therapy, corticosteroids would be effective and safe for the treatment of plastic bronchitis with hemoptysis.
    Acta Pharmacologica Sinica 09/2006; 27(9):1206-12. DOI:10.1111/j.1745-7254.2006.00418.x · 2.50 Impact Factor
Show more